NASDAQ:NBIX

Neurocrine Biosciences Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy NBIX

*Your capital is at risk

$175.77

+1.62 (+0.93%)

At Close: Jul 24, 2026

Neurocrine Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -78.39. In total, the insiders bought 811.91K and sold 403.71K NBIX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-78.39
● Buy	811.91K shares
● Sell	403.71K shares
70% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence May 19, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -78.39. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 21, 2026 Buy	Restricted Stock Unit M-Exempt	Mercier Johanna Director	Director	3 318 Value: $515.9K
May 21, 2026 Buy	Common Stock M-Exempt	Lyons Gary A Director	Director	1 659 Value: $258.0K
May 21, 2026 Buy	Common Stock M-Exempt	Sherwin Stephen A Director	Director	3 318 Value: $515.9K
May 21, 2026 Buy	Common Stock M-Exempt	Sharp Shalini Director	Director	1 659 Value: $258.0K
May 21, 2026 Buy	Common Stock M-Exempt	Rastetter William H Director	Director	3 318 Value: $515.9K
May 21, 2026 Buy	Restricted Stock Unit M-Exempt	Pops Richard F Director	Director	3 318 Value: $515.9K
May 21, 2026 Buy	Restricted Stock Unit M-Exempt	Poon Christine A Director	Director	3 318 Value: $515.9K
May 21, 2026 Buy	Restricted Stock Unit M-Exempt	Norwalk Leslie V Director	Director	1 659 Value: $258.0K
May 21, 2026 Buy	Restricted Stock Unit M-Exempt	Morrow George J Director	Director	3 318 Value: $515.9K
May 21, 2026 Buy	Common Stock M-Exempt	Mercier Johanna Director	Director	3 318 Value: $515.9K
May 19, 2026 Sell	Common Stock S-Sale	Gorman Kevin Charles Director	Director	245 088 Value: $37.8M
May 19, 2026 Buy	Common Stock M-Exempt	Gorman Kevin Charles Director	Director	205 088 Value: $8.87M
May 19, 2026 Buy	Non-Qualified Stock Option M-Exempt	Gorman Kevin Charles Director	Director	205 088 Value: $8.87M
May 15, 2026 Buy	Non-Qualified Stock Option M-Exempt	Pops Richard F Director	Director	15 000 Value: $718.4K
May 15, 2026 Buy	Common Stock M-Exempt	Pops Richard F Director	Director	15 000 Value: $718.4K
May 15, 2026 Sell	Common Stock S-Sale	Pops Richard F Director	Director	15 000 Value: $2.36M
May 12, 2026 Sell	Common Stock S-Sale	Norwalk Leslie V Director	Director	3 810 Value: $590.6K
Mar 15, 2026 Buy	Incentive Stock Option	Ratz Andrew Chief Technical Operations Off	Officer	805 Value: $99.9K
Mar 15, 2026 Buy	Non-Qualified Stock Option	Ratz Andrew Chief Technical Operations Off	Officer	31 348 Value: $3.89M
Mar 15, 2026 Buy	Non-Qualified Stock Option	Ratz Andrew Chief Technical Operations Off	Officer	17 724 Value: $2.66M
Mar 15, 2026 Buy	Common Stock	Ratz Andrew Chief Technical Operations Off	Officer	0 Value: $0
Mar 15, 2026 Buy	Restricted Stock Unit	Ratz Andrew Chief Technical Operations Off	Officer	5 640 Value: $991.3K
Mar 15, 2026 Buy	Incentive Stock Option	Ratz Andrew Chief Technical Operations Off	Officer	2 664 Value: $399.9K
Mar 04, 2026 Sell	Common Stock G-Gift	Abernethy Matt Chief Financial Officer	C-Suite Officer	2 249 Value: $0
Feb 20, 2026 Sell	Common Stock G-Gift	Onyia Jude Chief Scientific Officer	Officer	3 110 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT NEUROCRINE BIOSCIENCES

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ON...

Read Full Profile Here